RTX-224 Monotherapy in Patients With Solid Tumors

RTX-224 Monotherapy in Patients With Solid Tumors
Conditions:   Non Small Cell Lung Cancer;   Cutaneous Melanoma;   Head and Neck Squamous Cell Carcinoma;   Urothelial Carcinoma;   TNBC – Triple-Negative Breast Cancer
Intervention:   Drug: RTX-224
Sponsor:   Rubius Therapeutics

Source: View full study details on ClinicalTrials.gov

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. By listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.

February 3, 2022Comments OffClinicalTrials.gov | Oncology Clinical Trials | Oncology Studies | US National Library of Medicine